Ischemic heart disease is the leading cause of mortality in women and is associated with significant morbidity related to the clinical consequences of myocardial infarction (MI) and ischemia, such as heart failure. 1, 2 Women with ST-elevation myocardial infarction (STEMI) have worse short-term and long-term mortality than men, although these sex differences are often attributed to increased age and higher cardiovascular risk profile in women. [3] [4] [5] [6] Nevertheless, young women b65 years have higher mortality post-STEMI than age-matched men despite a lower prevalence of obstructive coronary artery disease (CAD). 4, 7 Treatment disparities have been implicated because women are less likely to receive guideline-recommended pharmacotherapy and reperfusion therapy compared with men and have longer times to treatment. [8] [9] [10] [11] [12] [13] [14] In addition, sex differences in the pathophysiology of STEMI (such as coronary plaque erosion and abnormal coronary vasomotor function) may lead to differences in administration of and response to guidelines-based STEMI therapy. 15 Whether the higher mortality in women is related to these treatment disparities remains controversial. We sought to determine whether a standardized STEMI protocol and an organized transfer system reduce treatment disparities in addition to short-term and long-term mortality in women versus men.
Methods
We studied patients enrolled from March 2003 to January 2016 in the Minneapolis Heart Institute STEMI system registry, which is a comprehensive, prospective database of STEMI patients who presented to the Minneapolis Heart Institute at Abbott Northwestern Hospital regional STEMI system. 16, 17 The Minneapolis Heart Institute Level 1 MI program is a percutaneous coronary intervention (PCI)-based regional STEMI system which includes 31 community hospitals and 10 clinics in Minnesota and Wisconsin using a standardized protocol and organized transfer system designed to improve time to treatment and clinical outcomes. The design of the system and initial results have been previously described. [16] [17] [18] [19] [20] In addition to the PCI center, patients are transferred from Zone 1 which includes 11 hospitals within 60 miles of the PCI center and Zone 2 with 20 hospitals between 60 and 210 miles away treated with a pharmacoinvasive protocol using half-dose fibrinolysis. 20 Standardized protocols including a transfer plan (ambulance or helicopter) were implemented for each site. We obtained Institutional Review Board approval for data collection, follow-up, and data analysis.
Inclusion criterion was STEMI or new left bundle-branch block in patients with chest pain of b24 hour's duration. No patients were excluded from the protocol unless reperfusion therapy was considered inappropriate, for example, in end-stage dementia or metastatic cancer. All STEMI patients, including those with out-of-hospital cardiac arrest, cardiogenic shock, advanced age, and initially nondiagnostic 12-lead electrocardiograms, were included in the registry. Demographic information, cardiovascular risk factors, door-to-balloon time (arrival at referral hospital to balloon at PCI center), STEMI characteristics, treatment, and clinical outcomes were recorded and stratified by sex. Patients were followed up for 5 years for survival analysis.
Descriptive statistics are displayed as means and SDs for continuous variables; number and percentage with characteristic are given for categorical variables. When continuous variables had skewed distributions (door-to-balloon times and length of stay), data are summarized with medians and 25th and 75th percentiles. Categorical variables were analyzed using Pearson χ 2 or Fisher exact tests. Continuous variables were analyzed using Student t test for normally distributed variables or Wilcoxon rank-sum tests for continuous variables with non-normal distribution. A value of P b .05 was considered significant, and P values are 2-sided where possible. For patients with known survival and event status, the fraction at each follow-up interval was estimated by Kaplan-Meier method. Cox regression models were used to adjust differences in age at presentation. Actual and expected surviving fractions were compared using the log-rank test. All statistical calculations and plots were done with Stata 14.1 (StataCorp, College Station, TX).
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Results
Data from 4,918 consecutive STEMI patients from March 2003 to January 2016 were analyzed including 28.8% women. Baseline characteristics for men and women are presented in Table I . Women were older with higher rates of hypertension, diabetes, and cardiogenic shock but lower rates of prior smoking and history of CAD including previous MI and revascularization. Women had lower body mass index (BMI), peak creatine kinase (CK), and CK-MB levels. There were no significant sex differences in percentage of anterior MI or ejection fraction. Women were less likely to have a culprit artery (77.2% vs 83.3%, P b .001) and, consistent with this more, frequently had Thrombolysis in Myocardial Infarction (TIMI) 2/3 flow (54.8% vs 48.2%, P b .001) at baseline angiography. There was no significant sex difference in pretreatment with aspirin, thienopyridine, or other antithrombotic prior to PCI (Table I) . When a culprit artery was identified, women had similar rates of PCI performed compared with men (94.4% vs 95.6%, P = .10) but had longer door-to-balloon time (median 61 vs 55 minutes at a PCI facility, P b .001; median 99 vs 94 at a Zone 1 facility, P b .001) (Table II) . There was no significant sex difference in door-to-balloon time at the Zone 2 facility (median 124 vs 121, P = .21). Overall, door-to-balloon within goal was achieved in fewer women than men for PCI and Zone 1 facilities but not significantly different for Zone 2 facilities. The median length of stay was not clinically significantly different between women and men (3 days for both). Women who received PCI were slightly less likely to be discharged on an aspirin, statin, and other antiplatelet agent compared with men (Table II) .
Compared with men, women had higher rates of unadjusted in-hospital mortality (7.6% vs 5.2%, P = .001) and 30-day mortality (8.4% vs 5.9%, P = .001) (Table III) . There were no significant sex differences in 30-day outcomes for MI, stroke, and revascularization.
After age adjustment, women continued to have similar outcomes to men including revascularization (95% vs 96%, P = .43) and length of stay (2.9 vs 2.7 days, P = .093), although door-to-balloon time (95 vs 92 minutes, P = .004) and percentage of goal door-to-balloon ≤120 minutes (71% vs 74%, P = .04) remained slightly worse for women compared with men. In-hospital mortality was no longer significantly different when adjusted for age (5.1% vs 4.8%, P = .60). Age stratification demonstrated that in-hospital mortality was highest in the group of men and women aged ≥80 years (Figure 1 ), but there was no significant sex difference in in-hospital mortality within each age subgroup, including young patients b60 years old. In addition, based on a multivariate model, female sex was not a significant predictor of in-hospital mortality (HR 1.042, 95% CI 0.860-1.261, P = .68). Five-year follow-up data confirmed the absence of sex disparity in survival post-STEMI with age adjustment (log-rank test: P = .35) (Figure 2 ).
Discussion
In this study, we demonstrate that in a regional PCI-based STEMI system using a standardized STEMI protocol and organized transfer system, treatment disparities in door-to-balloon time and discharge medications remained slightly worse for women compared with men, but prior reported sex disparities in STEMI in-hospital and 5-year follow-up mortality are not observed when adjusted for age. Female sex was not a significant predictor of mortality in a multivariate model, suggesting that biological sex differences are not a major factor in the sex disparity in post-STEMI mortality when using a standardized PCI-based STEMI protocol. These results are important, as the recently published STEMI data from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines demonstrated that (1) median contact-to-device time remains longer in women than men, (2) 32.5% of female STEMI patients did not meet the recommended target time of ≤90 minutes compared with 24.4% of male patients, (3) longer reperfusion time was associated with increased mortality for both women and men, and importantly (4) adjusted mortality rate was higher in female STEMI patients than male STEMI patients. 12 We demonstrate that in a PCI-based STEMI system using a standardized STEMI protocol and reduced treatment disparities, female sex is no longer a predictor of mortality.
Sex differences in reperfusion time
Our findings are pertinent given the recent findings from 2 studies of contemporary young STEMI patients: (1) the "Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients" (VIRGO) study, which identified sex disparities in 1,238 young patients (b55 years) with STEMI eligible for reperfusion from 2008 to 2012 in the United States, 11 and (2) the Nationwide Inpatient Sample database, which evaluated 632,930 patients b60 years In-hospital mortality stratified by patient age and sex. Age stratification demonstrated that in-hospital mortality was not significantly different between women and men across age groups. These 2 studies demonstrated that young women with STEMI were less likely to undergo coronary angiography and less likely to receive revascularization compared with young men in the United States. Of the patients who received revascularization, young women also experienced more delays in reperfusion than men, despite adjustment for sociodemographics, comorbidities, and clinical factors, with the most significant sex-specific delays being door-to-needle time for fibrinolytic therapy and door-to-balloon times for patients being transferred for PCI. In VIRGO, recommended timeframe guidelines were exceeded in more women than men, particularly for the transfer patients (door-to-balloon N120 minutes: 67% vs 44%, P b .001). 11 Older age is a known independent predictor of achieving goal reperfusion time, 13 which suggests a delay in younger patients-a group that may be more susceptible to sex differences. 22 Standardized protocols have been shown to improve reperfusion times with integrated transfer systems, which may in turn decrease sex discrepancy in reperfusion time. 16, 23 In the HORIZONS-AMI randomized trial of patients with STEMI undergoing primary PCI, door-to-balloon time was not significantly different in women vs men (102 vs 98 minutes, P = .19). 24 Unfortunately, recent evaluation of N14,000 STEMI patients in the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines database showed that first medical contact to device time ≤120 minutes was not achieved in 35% of patients who require transfer for primary PCI, even when restricting analysis to patients who are within 60 minutes of the PCI center. 13 In our study of the Minneapolis Heart Institute STEMI system registry, we identified minimal sex differences in door-to-balloon time and percentage of door-to-balloon within goal, but we had lower percentage of men (21.7%) and women (27.8%) surpassing door-to-balloon N120 minutes in Zone 1. This demonstrates that a standardized STEMI system reduces reperfusion delays and likely contributes to improved STEMI outcomes for women.
Reperfusion time and mortality
The sex disparities in reperfusion time for young STEMI patients may explain why these prior studies have shown a higher mortality in young women with STEMI than men. The VIRGO analysis found that 1-month and 1-year mortality rate was higher in young patients who exceeded the recommended reperfusion goals (including nontransfer and transfer door-to-balloon times for PCI and fibrinolysis door-to-needle times) than patients who met the recommended reperfusion guidelines, although the mortality rates were low and thus could not be adjusted for sex or age. The Zwolle Myocardial Infarction Study Registry, which studied 6,746 STEMI patients referred for primary PCI from 1998 to 2008 in the Netherlands, also demonstrated sex differences in reperfusion time and 1-year mortality in young patients b65 years. 4 Although our study is underpowered for analysis of sex differences in young STEMI patients, we did not see a statistically significant sex difference in mortality for patients b60 years old.
Improved reperfusion times translate to lower mortality rates. [24] [25] [26] In our analysis of the Minneapolis Heart Institute regional STEMI system database, we did not find a significant sex difference for in-hospital mortality or 5-year mortality when adjusted for age. The lack of significant sex differences when stratified by age may be due to the standardized treatment strategies with very high rates of guideline-based medications pre-revascularization and at discharge, although we did find a slightly lower percentage of women receiving statin, aspirin, and other antiplatelet agents at discharge. Our findings are consistent with those of the HORIZONS-AMI trial, which determined that female sex was not an independent predictor of long-term major adverse cardiovascular events at 3 years after adjusting for differences in baseline and treatment characteristics. 24 Sex differences in cardiovascular risk markers and postdischarge management Although the studies above emphasize sex differences in reperfusion as important modifiable predictors of STEMI mortality, sex-related differences in cardiovascular risk markers should not be dismissed as factors contributing to mortality and postdischarge treatment disparities. Our finding that women with STEMI have poorer baseline cardiovascular risk profile (specifically hypertension and diabetes) is consistent with prior studies and may be related to age. 27 Nevertheless, sex-related biological differences include increased mortality associated with diabetes and higher risk of ischemic heart disease if smoking. 28 Sex differences in cardiac enzymes and STEMI symptoms may also contribute to suboptimal prediction of a woman's STEMI risk-and thus STEMI management. 29 Given the lower total infarct size (as measured by CK-MB) and the higher pre-PCI TIMI flow in women, women may be expected to have lower mortality than men. However, women had a smaller BMI than men, and the post-PCI TIMI flow rates were not different between women and men in our study. Women have also been reported to have worse morbidity than men following STEMI, including short-term and long-term bleeding and major adverse cardiovascular events. 24 Finally, female sex has also been associated with the underutilization of angiotensin-converting enzyme inhibitors, β-blockers, statin, and cardiac rehabilitation utilization post-MI. 2 Indeed, of the patients who received PCI in our STEMI registry, guidelines-based pharmacotherapies (antiplatelet and statin) were less frequently prescribed in women compared with men at the time of discharge. We did not determine whether sex differences in bleeding complications, cholesterol levels, or statin intolerance contributed to the mild disparity in discharge prescription rates of these guidelines-based pharmacotherapies. Although we did not find a difference in age-adjusted 30-day or 5-year mortality, physicians and the community should be educated regarding sex-related differences in cardiovascular risk, morbidity, and pharmacotherapy to ultimately improve long-term cardiovascular outcomes.
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Limitations
Because our study included only STEMI patients enrolled in the registry, we do not have a contemporary control group that did not participate in the standardized STEMI protocol. Thus, our comparison of sex disparities is based on historical control data from prior published STEMI studies. We also did not perform subgroup analysis for STEMI patients younger than 60 given the small sample size in this age group. All patients with STEMI were included in our outcomes analysis, including patients with coronary artery spasm, Takotsubo cardiomyopathy, and spontaneous coronary artery dissection, which are conditions that are more common in women and may have different management and prognosis compared with STEMI from ruptured plaque. [32] [33] [34] [35] [36] Treatment times are also included for all patients including complex situations such as patients who developed ST elevation after the initial electrocardiogram or patients with prolonged resuscitation. There is a possible oversampling of men, as there were approximately 2.5× more men than women in our registry. However, this is consistent with the proportion of women in other STEMI registries. In addition, race and ethnicity were typical of a Minnesota population (95% white, 2%-3% African American, 1% Asian, 1% Hispanic, and~1% other). Although there was no statistical difference across groups, the demographics of our population may not be reflective of the US population. Finally, our 5-year survival analysis was adjusted for age and not adjusted for other baseline characteristics.
Conclusions
The previously reported treatment disparities between men and women are diminished in a regional PCI-based STEMI system using a standardized STEMI protocol, with no sex differences in age-adjusted mortality. These results suggest that STEMI health care disparities and mortality in women can be improved using STEMI protocols and systems. Larger data sets with fully risk-adjusted models and longer follow-up are needed to assess mortality differences in younger women and longer-term mortality.
